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Abstract
Heritable cardiac amyloidosis (CA) is an underrecognized cause of morbidity and mortality in the USA. It results from the
accumulation of the misfolded protein transthyretin within the myocardium, resulting in amyloid transthyretin-associated
cardiomyopathy (ATTR-CM). Over 150 different pathologic point mutations within the transthyretin gene have been identified, each carrying variable clinical phenotypes and penetrance. In the USA, the most common cause of hereditary ATTR is
the Val122Ile point mutation, with a prevalence of 3.4–4.0% in North Americans of African and Caribbean descent. Among
Caucasians with hereditary ATTR-CM, the V30M mutation is the most commonly identified variant. Overall, the incidence
of ATTR disease in the USA has been increasing, likely due to an increase in practitioner awareness, utilization of new
non-invasive imaging technologies for ATTR diagnosis, and the growth of multidisciplinary amyloid programs across the
country. Yet significant numbers of patients with evidence of left ventricular thickening on cardiac imaging, senile aortic
stenosis, and/or symptoms of heart failure with preserved ejection fraction likely have undiagnosed CA, especially within
the African American population. With the emergence of new disease-modifying therapies for ATTR, recognition and the
prompt diagnosis of CA is important for patients and their potentially affected progeny. Herein, we review the genetics of
heritable CA as well as the importance of genetic counseling and testing for patients and their families.
Keywords: Amyloid, Cardiomyopathy, Genetics, Phenotype,
Genotype, Inheritance.

Overview of heritable amyloidosis
Heritable amyloidosis represents the fraction of amyloid
diseases driven by genetic mutations, occurring most commonly within the transthyretin (TTR) gene. Other much rarer
heritable forms of amyloidosis can be found in patients with
mutations in the fibrinogen A alpha chain, apolipoprotein A1
and A2, gelsolin, LECT2, and cystatin C genes [1–6]. However, all heritable amyloidoses follow an autosomal dominant manner of transmission. The number of amyloidosis
cases in the USA has risen dramatically in the past 25 years,
with the greatest rise in the heritable and senile amyloidosis diagnoses over the past decade. These changes are more
likely related to improved practitioner awareness, increased
patient screening, better non-invasive imaging techniques,
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and the availability of disease-modifying treatment options
[7]. Though heritable amyloid is still rare, it is a phenotypically diffuse disease with inconsistent penetrance that makes
its diagnosis challenging; understanding its molecular and
genetic basis is important for prompt diagnosis, testing, and
counseling of patients and their families.

The transthyretin gene
Transthyretin (TTR, also called pre-albumin), the predominant source of heritable cardiac amyloidosis, is a 127 amino
acid, 56 kDa homo-tetrameric transport protein encoded by
the TTR gene on human chromosome 18q12.1. TTR is transcribed mainly within cells of the liver but can also be found
in the choroid plexus, pancreatic islet cells, various parts of
the brain, and the retina [8]. Its primary role in humans is to
TRANSport THYroxine and RETINol bindign protein, the
roles of which were used to derive the protein’s name. TTR
is present in all vertebrates and is integral for the function
of multiple organ systems, including the eyes, nerves, heart,
bone, and muscle.
Over 150 different mutations have been found in the TTR
gene, most of which have been pathologically linked to
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heritable TTR amyloid (hATTR) [9]. The amyloidogencity
of a particular mutation stems from the resultant protein’s
secretion efficiency and the ability of a given mutation to
destabilize the homo-tetrameric structure of TTR, resulting
in fibril accumulation within organs [10, 11]. Hereditary
ATTR phenotypes vary greatly between mutation types,
leading to differences in organ selectivity, disease severity,
and patient prognosis. The vast majority of hATTR mutations are gain of function mutations and thus transmit in
an autosomal dominant manner. However, phenotype and
penetrance can be highly variable even within cohorts carrying the same mutation. Rare families with duplications or
codon deletions within TTR have also been reported [12,
13], as have patients with homozygous and mixed heterozygous pathogenic genotypes [13–15].
Because hATTR is a genetic disease, geographical and
ethno-racial clustering is noted across the world. The most
common hATTR mutation globally is Val30Met, responsible
for familial autonomic neuropathy (FAP) type I, predominantly found in Europe. In the USA, however, the most common form of hATTR, Val122Ile, is almost exclusively found
in those of African and Caribbean descent. The diversity of
the USA and the variable presentation of heritable amyloidosis warrant discussion of the several key hATTR mutations
outlined in Table 1.

Transthyretin mutations most associated
with heritable cardiac amyloidosis
in the USA
Val122Ile cardiac amyloidosis
Val122Ile (also known as pV142I) is a point mutation in
the TTR gene, resulting in the substitution of isoleucine
for valine at position 122. It confers a similar phenotype
to wild-type ATTR and is the most common subtype in
the U.S. [13, 16–18]. While allele frequency for V122I in
the U.S. is 0.0173, 3.4–4.0% of US individuals of AfroCaribbean descent are believed to be carriers—between
one and two million Americans [19, 20]. These patients
are underrepresented in the Southern U.S. despite having

larger populations of self-identified African Americans,
almost certainly reflective of American healthcare disparities and CA underdiagnosis [21]. Although the true
phenotypic penetrance of the Val122Ile mutation is not
yet known, 10% of African Americans over age 60 with
heart failure are estimated to be ValI122Ile positive [22],
and carriers of the V122I mutation are 2 to 3 times more
likely to develop heart failure compared to age, gender, and
racially matched controls [12, 19].
The disease onset in all affected V122I patients is late—
almost always after the age of 60—though it is unknown
what factors influence who will be affected [19, 24, 25].
Despite its low penetrance, all V122I carriers 65 years and
greater accumulate myocardial amyloid to some degree.
The severity of accumulation, however, varies substantially
between individuals, leaving some with severe heart disease
while others are left with no or mild symptoms. Men are
more than three times as likely to be affected than women
despite carrying the mutation at equal frequencies; this is
the case for nearly all ATTR subtypes, albeit in different
ratios [12, 19].
Unlike other mutations, Val122Ile carriers display
fewer and less debilitating neurologic complications;
autonomic dysfunction in these patients is either absent
or subtle. This is in stark contrast to V30M/FAP type 1
patients who often present with severe sensorimotor and
automatic neuropathies. Many V122I patients have no
neurologic symptoms, but among those who do, carpal
tunnel syndrome (CTS) and spinal stenosis are most common. This represents only 20–30% of amyloid patients,
but the diagnosis of CTS can precede amyloidosis development by 5 to 9 years [26]. Diagnosis in an older patient,
especially when bilateral, confers a 12-fold risk for a
future CA diagnosis and should prompt concern [27, 28].
Other signs or symptoms that warrant further work-up
include biceps or Achilles tendon rupture, gastrointestinal
dysmotility, glaucoma, and new-onset cardiac conduction
disorders.
As mentioned, V122I hATTR is very similar to senile
amyloidosis, though there are important distinctions.
Patients with V122I hATTR-CA present a median of 5 years
younger than most wild-type ATTR cardiomyopathy patients

Table 1  Several key hATTR mutations
Mutation

Penetrance

Frequency/area

Ethnicity

Neuropathy

Cardiac

Onset

Wild-type
V122I
V30M early
V30M late
T60A

NA
Low
High
Low
Low

NA
3.4–4%
< 0.2%
1–2%
~ 1%

Caucasian
African/Caribbean American
Portuguese, Japanese
Swedish, Japanese
Irish, US Appalachian

No
Mild or rare
Severe
Frequent
Frequent

HFpEF
HFpEF
Arrhythmia
HFpEF > arrhythmia
HFpEF

> 70 y
> 60 y
> 30 y
> 50 y
> 60 y

Frequency/area indicates frequency specific to endemic areas. Ref: [13, 19, 30, 75, 76]
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[18, 23, 24]. They tend to have greater septal thickness and
are more likely to have right-sided hypertrophy as well [19,
25]. Epidemiologic data have also indicated that the mutant
phenotype has worse outcomes, worse quality of life, and
likely worse survival when compared to wild-type ATTRCA patients [18, 23]. However, given that V122I disease
(unlike wild-type ATTR) disproportionately affects African
Americans, it is difficult to discern if this difference reflects
the disease process per se, or the overall poorer healthcare
outcomes for people of color in the USA [29].

Thr60Ala amyloidosis
The second most common hATTR genotype in the USA is
the Thr60Ala mutation [17]. T60A is the most common isoform in the UK, predominantly affects Caucasians, and confers a phenotype with features of V122I and Val30Met, the
mutation responsible for familial amyloid neuropathy type I
(discussed below) [30]. Populations of Thr60Ala patients are
found throughout the USA; however, the carrier frequency
is highest in Donegal County of Northern Ireland, affecting
about 1% of the population (Table 1) [17, 30, 31]. Carriers
in the USA have been found in Appalachia, New York, and
the Mid-West, the families of whom likely originally immigrated from Europe through a common founder [17, 32, 33].
As with other forms of amyloidosis, spontaneous mutant
ATTR cases of T60A have also been reported [34, 35].
Like V122I, T60A also has a low penetrance with a lateonset presentation. The disease usually occurs after age 60
and also has a male predominance, with a phenotypic ratio
of 2:1 as opposed to 3:1 in V122I [12, 19]. However, these
patients present with both cardiac disease and neuropathy,
the latter of which usually affects somatic and autonomic
fibers [30, 31]. Neurologic manifestations tend to be less
severe than in Val30Met disease, though T60A patients have
comparatively more cardiac manifestations, which is consistent with their somewhat higher mortality than V122I cohorts
[30, 32].

Val30Met: familial amyloid neuropathy
The most common amyloid mutation worldwide, Val30Met,
is responsible for familial amyloid neuropathy type I [13,
15, 36]. FAP is a rare disease worldwide and uncommon
in North America, predominantly affecting US residents of
Portuguese, Swedish, and Japanese descent with a 2: 1 male
phenotypic predominance [37]. The Val30Met mutation is
strongly penetrant in most kindreds (> 69%), and affected
individuals experience severe, progressive, degenerative sensory, autonomic, and motor neuropathy. Rather than heart
failure, Val30Met patients are more likely to suffer from
cardiac conduction disturbances and syncope attributed to
autonomic dysfunction [38–41].

There are several distinct populations of FAP patients
that, despite a common genotype, have distinct phenotypes
that can be further categorized into early- and late-onset
FAP.
The Portuguese- and Japanese-predominant forms have
an early age of onset (30 s) and a higher penetrance than
the Swedish variant, the latter of which occurs later in life
with a much lower penetrance and more indolent course [38,
40–42]. Both variants are more likely to manifest cardiac
conduction disturbances than heart failure; however, lateonset FAP is more associated with heart failure with preserved ejection fraction (HFpEF) than early-onset disease
(Table 1) [43, 44].
The explanation for differences between late-onset and
early-onset phenotypes is unclear. As in wild-type and V122I
disease, there are also sex-specific differences in phenotype
that influence the age of disease onset [45]. Portuguese
women with the V30M mutation demonstrate an older age of
onset compared to male carriers and are more likely to pass
along disease to their sons, who then present with symptoms
at an increasingly earlier age of onset [45]. Anticipation is
also apparent in early- and in some late-onset (> 50 years)
cohorts among Spanish and Japanese kindreds, though this
has not been reported with V122I carriers [46–49].
There also appears to be greater penetrance in carriers
who have inherited the TTR mutation from their mothers
than from their fathers [40, 44]. This may be influenced
by mitochondrial inheritance; however, the mechanism for
gender-based differences remains an open question [50, 51].
Finally, a second mutation, T119M, has been identified in a
small proportion of patients with the V30M mutation who
have no or mild disease, yielding a mixed heterozygous
genotype (V30M/T119M) that appears protective. T119M
stabilizes tetrameric TTR, slowing amyloid fibril formation
and was a key impetus in the development of tafamidis [12].

Amyloidosis: the role of epigenetics
and the environment
Epigenetics may play a significant role in determining
which carriers will ultimately develop clinically significant
hATTR disease and when [52, 53]. Epigenetics is the study
of extra-genomic, potentially heritable processes that alter
the expression of a gene and phenotype through biochemical modification of the nucleotide backbone or its associated chromatin. In addition to the variable penetrance and
sex-based differences in phenotype among ATTR patients,
monozygotic twins who carry hATTR mutations have also
shown marked discordance in the expression of cardiac
amyloid disease, necessitating the involvement of either
epigenetic, trans-regulatory, and/or environmental factors
[54, 55]. Epigenetic studies of hATTR patients have shown
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differences in methylation profiles between Val30Met and
Val122Ile carriers and their respective wild-type controls—
changes which can be inherited [56, 57]. However, it is
unclear at this time what causative role these differences
may have in amyloid pathology [56, 57]. Epigenetic modifications of cardiac myocyte DNA (commonly through methylation) have been shown to be dynamic during development
and into adulthood. Individuals with heart failure have demonstrated DNA methylation leading to transcriptional reprogramming, and such changes may also account for some of
the phenotypic variability in amyloidosis [58, 59].
Hereditary ATTR, irrespective of genotype, also occurs
on a heterogeneous genetic background of patients who may
have other risk factors for diastolic dysfunction, including
hypertension, obesity, and diabetes [60, 61]. Environmental stimuli and aging can influence gene expression through
trans-regulatory elements in animal models [62, 63]. However, it is unknown how environmental stimuli, such as stress
or hypertension, can influence the disease course of CA—if
at all. Alzheimer’s disease, also an amyloidopathy, has been
linked to hypertension and smoking in the decades prior to
disease onset [64–66]. Risk factors for heart disease may
similarly influence the age of onset and penetrance of both
mutant and wild-type ATTR-CA, though this has yet to be
demonstrated among ATTR cohorts.

Role for genetic testing and counseling
Patients diagnosed with ATTR amyloidosis should be
offered the opportunity to undergo genetic testing, regardless of family history, especially if they have progeny or
siblings who are at risk for heritable disease [22]. The utility
of genetic testing in patients with non-AL forms of amyloid
(hereditary or wild-type TTR amyloid) who lack biological
siblings or children is less clear, but it may be helpful when
other testing is inconclusive or mixed amyloid disease (e.g.,
AL and hereditary amyloid) is of concern. Wild-type and
V122I-ATTR are often clinically indistinguishable diseases,
and while a detailed family history is obligatory, that alone
is insufficient for identifying familial ATTR or a subtype
[22, 30, 35]. Moreover, the presence of a pathogenic amyloid mutation has important implications for asymptomatic
biological family members as discussed below.
When testing patients, it is important to consider that
there are numerous mutations associated with hATTR and
undoubtedly additional mutations are likely to be discovered.
While most patients with hATTR will be heterozygous for a
single mutation, patients with homozygous mutations have
been identified. Such patients do not necessarily fare worse
than those carrying a single mutant copy, but homozygosity
has important implications for genetic counseling [14, 67,
68]. Patients can also be double heterozygous for different
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hATTR mutations, and duplications have been reported in
ATTR as well [13, 15, 69]. Fortunately, genetic testing for
known pathologic missense mutations is rapid and can be
undertaken using blood, saliva, or buccal specimens with
increasingly approved coverage by payors. In patients for
which a provider has a high clinical suspicion for hATTR
despite negative or ambiguous genotype results, more
sophisticated genetic testing can be undertaken to detect
deletions or duplications, or more commonly, tissue samples can be sent for mass spectrometry proteomic analysis,
which can differentiate mutant ATTR protein from wild-type
or other amyloid deposits in tissue [8].

The process of genetic counseling
Once a pathologic mutation has been identified, the implications for that person’s family can be a difficult process to
navigate and replete with ethical and financial issues. Thus,
genetic counseling should accompany all decisions to obtain
hATTR testing and should predate sample acquisition in
both patients and blood relatives [70, 71]. Genetic counseling can be done formally, via a licensed individual, or
informally by experienced hATTR practitioners. The genetic
counseling encounter is a shared decision-making process that mandates an interactive, bidirectional discussion
between the patient and the provider/counselor. The provider/counselor shares information appropriate to a patient’s
educational level about the disease process, its heritability,
and the potential risks and benefits of testing. Additionally,
the provider/counselor should highlight the equally important emotional considerations about genotyping, including
intrapersonal stress regarding potential transmission of a
mutation to offspring and anxiety offspring may face when
confronted with an affected family member’s diagnosis.
Teach back should be used to ensure patients and families
comprehend the information offered. The counseling visit
should also discuss the protections and risk associated with
genetic testing, and informed consent should be obtained
prior to sending samples for analysis.
When the decision to genotype a patient has been
made, samples should be sent to institutions or companies
accredited by the College of American Pathologists (CAP)
and with Clinical Laboratory Improvement Amendments
(CLIA) certification. Both positive and negative results
warrant further discussion, offering an opportunity to
answer additional questions and address the timing and
decision to disclose positive results to first degree relatives. It is often beneficial for the provider or genetic counselor to assist in leading these complex discussions. The
availability of virtual encounters can afford several family
members the opportunity to learn about hATTR screening and local resources for amyloid evaluation and genetic
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testing as appropriate. It is important to emphasize that (1)
the presence of a mutation is not equivalent to diagnosing
amyloid disease, (2) a mutation in TTR does not necessarily determine the severity or distribution of amyloid, and
(3) not all mutations causing amyloid have been detected.
For relatives of a patient who undergo testing for
hATTR and return genotype-positive, many will have no
phenotypic expression of the disease. However, the disclosure of a pathogenic genotype to patients and at-risk
family members has the potential to produce anxiety about
their future or trigger guilt in those relatives who are genotype negative. Testing may also uncover non-paternity that
itself may cause emotional turmoil [72–74]. The risks of
genotyping are not merely psychological. While a 2008
federal law, the Genetic Information Nondiscrimination
Act (GINA), prohibits health insurance and employers
with > 15 employees from genetic discrimination, life,
long-term care, and disability insurance policies can
consider these results, and individuals undergoing testing should be aware of this. While hATTR patients will
likely have their disease discoverable through other medical tests, such as echocardiography, first degree relatives
should be counseled to consider obtaining life and disability insurance prior to genetic testing, so they legally have
no symptoms nor knowledge of genotypic risk for hATTR.
Asymptomatic minors, who cannot consent to genetic
testing and may not appreciate the emotional or financial
implications of knowing their carrier status, should delay
genetic testing until adulthood.

Summary
With cardiac amyloid is an increasingly recognized cause of
mortality and morbidity among US adults, a high clinical suspicion of ATTR-CA in at-risk patients is imperative. Between
10 and 20% of patients hospitalized or being treated for conditions like HFpEF or aortic stenosis may have undiagnosed
amyloidosis, representing significant, unrealized opportunities
for treatment and intervention in these patients. This is particularly true of persons of color who are likely being underdiagnosed and undertreated in many areas of America.
There are now multiple FDA-approved medical therapies
that can either slow the progression of hATTR amyloid or
improve quality of life. However, these therapies are most
effective in those with early staged disease. The variable penetrance of TTR mutations, such as V122I, means that the diagnosis of even elderly patients with advanced disease can have
important therapeutic implications for a patient’s relatives,
potentially delaying the onset of illness in those ultimately
affected.
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